Do you want to read an article? Please log in or register.
Immunotherapy and PARP inhibitors as first-line treatment in endometrial cancer: A systematic review and network meta-analysis
Gynecologic Cancer
Related content
Lung, Respiratory and Thoracic Cancer
Systematic review and network meta-analysis of lorlatinib with comparison to other anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) as first-line treatment for ALK-positive advanced non-smallcell lung cancer (NSCLC)
Lung Cancer
Ou SH, Kilvert H, Candlish J, Lee B, Polli A, Thomaidou D, Le H
doi: 10.1016/j.lungcan.2024.107968
RECOMMENDED
Gynecologic Cancer
First-line treatment of locally advanced cervical carcinoma: An updated systematic review and Bayesian network meta-analysis
★ 1
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
Cancer Treat Rev
Petrelli F, Riboldi V, Bruschieri L, Villa A, Cribiu' FM, Borgonovo K, Ghilardi M, Ghidini A, Seghezzi S, Stefani A, Trevisan F
doi: 10.1016/j.ctrv.2025.102921
Lung, Respiratory and Thoracic Cancer
Comparative effectiveness and safety of tislelizumab versus other anti-PD-(L)1 agents in first- and subsequent lines in locally advanced or metastatic non-small cell lung cancer: Systematic literature review and network meta-analysis
Lung Cancer
Girard N, Han JY, Soo RA, Wang K, Tang W, Nikolaidis GF, Tasoulas A, Barouma I, Castro JC, Yang Z, Chaudhary T, Zhan L
doi: 10.1016/j.lungcan.2025.108450
Lung, Respiratory and Thoracic Cancer
Chemotherapy plus immunotherapy as first line combination in older patients with extensive stage small cell lung cancer: A systematic review and meta-analysis
Semin Oncol
Bertaglia V, Petrelli F, Dottorini L, Carnio S, Morelli AM, Nepote A, Maccioni A, Scartozzi M, Solinas C, Novello S
doi: 10.1053/j.seminoncol.2024.11.001
Gastrointestinal Cancer
Exploring the Impact of first-line Durvalumab plus chemotherapy on advanced biliary tract cancer: A Systematic Review and Meta-Analysis
Oncologist
Reimann P, Schneider EM, Djanani A, Mink S, Winder T, Benda M
doi: 10.1093/oncolo/oyaf224
Further Publications
Frailty and outcomes in adults undergoing systemic anti-cancer treatment: a systematic review and meta-analysis
J Natl Cancer Inst
Pearce J, Martin S, Heritage S, Khoury EG, Kucharczak J, Nuamek T, Cairns DA, Velikova G, Richards SH, Clegg A, Gilbert A
doi: 10.1093/jnci/djaf017
Genitourinary Cancer
Efficacy of Treatments for T3bN0M0 Prostate Cancer Patients: A Systematic Review and Meta-Analysis
Prostate
Reijnen C, Heemsbergen WD, Wever KE, Panneflek A, Pos FJ, Michiel Sedelaar JP, van der Heide UA, Incrocci L, Jan Smeenk R
doi: 10.1002/pros.70024
Lung, Respiratory and Thoracic Cancer
Treatment sequences in BRAF-V600-mutated non-small cell lung cancer: First-line targeted therapy versus first-line (chemo-) immunotherapy
J Thorac Oncol
Wiesweg M, Alaffas A, Rasokat A, Saalfeld FC, Rost M, Assmann C, Herster F, Hilbrandt M, Griesinger F, Kron A, Roeper J, Glanemann F, Kropf-Sanchen C, Reck M, Kulhavy J, Stenzinger A, Wolf J, Sebastian M, Schuler M, Wermke M, Frost N, Kopp HG, Christopoulos P, Scheffler M
doi: 10.1016/j.jtho.2025.04.016
Breast Cancer
Long and short-term efficacy and safety comparison of nab-paclitaxel versus paclitaxel combined with trastuzumab and pertuzumab for neoadjuvant treatment of HER2-positive breast cancer: A systematic review and meta-analysis
Cancer Treat Rev
Yuan Y, Long X, Wei M, Chen L, Zhang J, Liu X
doi: 10.1016/j.ctrv.2025.102975